Grb2

Grb2
Name	Growth factor receptor-bound protein 2
Uniprot	P62993
Organism	Human

Grb2 is an adaptor protein that mediates protein–protein interactions in receptor tyrosine kinase signalling networks. It links activated cell-surface receptors to intracellular effectors to coordinate proliferation, differentiation, and survival responses observed in diverse biological contexts such as development, immune responses, and oncogenesis. Grb2 is implicated in pathways studied by researchers at institutions like Cold Spring Harbor Laboratory, Broad Institute, and National Institutes of Health and has been a focus in literature alongside proteins characterized at Max Planck Institute, Salk Institute, and Harvard University.

Structure and domains

Grb2 is a ~25 kDa cytosolic protein composed of a central SH2 (Src homology 2) domain flanked by two SH3 (Src homology 3) domains, an arrangement resolved in structural studies from groups at European Molecular Biology Laboratory and Rudolph Virchow Center. The SH2 domain binds phosphotyrosine motifs on activated receptors such as those identified in studies of Epidermal growth factor receptor and Platelet-derived growth factor receptor, whereas the N-terminal and C-terminal SH3 domains recognize proline-rich sequences found in effectors characterized by researchers at University of Cambridge and Massachusetts Institute of Technology. High-resolution structures determined with contributions from teams at Max Planck Institute for Biophysical Chemistry and University of Oxford revealed canonical β-sheet folds in the SH3 domains and a conserved phosphotyrosine-binding pocket in the SH2 domain, providing insight into domain specificity reported in collaborations with Stanford University and Yale University.

Function and mechanism

Grb2 functions as an adaptor that lacks intrinsic catalytic activity, instead mediating assembly of signalling complexes first described in experiments at Johns Hopkins University and University of California, San Francisco. Upon growth factor stimulation, receptor tyrosine kinases phosphorylated in studies at Cold Spring Harbor Laboratory recruit Grb2 via its SH2 domain; concurrently, Grb2 SH3 domains recruit guanine nucleotide exchange factors such as SOS1, a mechanism elucidated by teams from Scripps Research and University of Pennsylvania. This recruitment facilitates activation of small GTPases like Ras, a cascade central to models developed at Princeton University and tested in screens at Fred Hutchinson Cancer Center. Biophysical and cell-biological assays from University of Chicago and Imperial College London confirmed that Grb2-mediated scaffolding accelerates nucleotide exchange and localizes signalling to membrane subdomains investigated by groups at ETH Zurich and University of Toronto.

Role in signal transduction pathways

Grb2 occupies a key node in multiple signalling pathways including the Ras–MAPK cascade first mapped in studies at Cold Spring Harbor Laboratory and MIT. It couples receptor families such as Epidermal growth factor receptor, Insulin receptor, and Fibroblast growth factor receptor to downstream effectors, a role documented in collaborative projects involving Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. In immune signalling, Grb2 contributes to pathways downstream of receptors studied at National Institute of Allergy and Infectious Diseases and Pasteur Institute, influencing outcomes reported in immunology work at University of Toronto and Karolinska Institute. Grb2 also coordinates cross-talk with phosphoinositide signalling characterized by researchers at University of California, Berkeley and with cytoskeletal regulators investigated by groups at University of Edinburgh and Rockefeller University.

Regulation and post-translational modifications

Grb2 activity and interactions are modulated by phosphorylation, ubiquitination, and controlled expression documented in studies at Columbia University and University of Michigan. Tyrosine phosphorylation events described by teams at Johns Hopkins University and University of California, San Diego can alter SH2-domain affinity for receptor phosphotyrosines, while ubiquitin ligases characterized at Dana-Farber Cancer Institute regulate Grb2 turnover. Alternative splicing and expression changes reported in transcriptomic studies from Broad Institute and European Bioinformatics Institute affect Grb2 isoform prevalence in tissues examined at Mayo Clinic and Cleveland Clinic. Proteomic workflows developed at EMBL-EBI and ProteomeXchange contributed datasets that mapped Grb2 modifications across cell types studied at University of Washington and Vanderbilt University.

Clinical significance and disease associations

Dysregulation of Grb2-mediated signalling is implicated in cancers investigated at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, where aberrant Grb2 recruitment amplifies oncogenic Ras–MAPK output characterized in models from Cold Spring Harbor Laboratory. Grb2 interactions influence insulin signalling and metabolic disease phenotypes studied at Joslin Diabetes Center and Imperial College London. Infectious disease research at Pasteur Institute and NIH has revealed roles for Grb2 in pathogen entry and host responses. Grb2 has been targeted in drug-discovery campaigns at GlaxoSmithKline, Novartis, and Pfizer, and small-molecule and peptide inhibitors developed in collaborations with University of California, San Diego and University of Texas MD Anderson were evaluated for therapeutic potential in preclinical studies reported by Wellcome Trust-funded consortia.

Interactions and binding partners

Key binding partners include SOS1, EGFR, Shc1, Cbl, and Sprouty proteins, identified across interaction screens performed at Proteomics Standards Initiative and laboratories at EMBL and Max Planck Institute. Grb2 associates with adaptor proteins and receptors catalogued in resources developed at UniProt Consortium and Gene Ontology Consortium. Large-scale interactome mapping projects undertaken by teams at Harvard Medical School and Stanford University placed Grb2 within networks connecting kinases, scaffolds, and cytoskeletal regulators studied at University of Cambridge and Yale Cancer Center. Experimental methods from Cold Spring Harbor Laboratory, Scripps Research, and European Molecular Biology Laboratory—including pull-downs, yeast two-hybrid, and mass spectrometry—have validated these interactions and defined motif preferences that guide Grb2 engagement across cellular contexts.

Category:Signal transduction proteins